Pyxis Oncology Q2 2025 net loss $18.4M, cash $90.4M; MICVO data milestones ahead

Pyxis Oncology, Inc.

2025-Q2 EPS reported -$0.64 vs consensus -$0.36 ▼ miss (-78.4%)

Revenue of $2.8M from milestone payment for suvemcitug approval in China, compared to $0 in Q2 2024.
Net loss $18.4M ($0.30 per share) vs $17.3M ($0.29) in prior year; adjusted loss $15.3M.
Cash, cash equivalents and short-term investments $90.4M; runway into H2 2026.
Preliminary MICVO monotherapy data in 2L/3L HNSCC expected H2 2025; combination with pembrolizumab data also H2 2025.
R&D expenses rose to $17.1M, driven by increased MICVO manufacturing and trial costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.